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Abstract
Viruses that generate capped RNA lacking 29O methylation on the first ribose are severely affected by the antiviral activity of
Type I interferons. We used proteome-wide affinity purification coupled to mass spectrometry to identify human and mouse
proteins specifically binding to capped RNA with different methylation states. This analysis, complemented with functional
validation experiments, revealed that IFIT1 is the sole interferon-induced protein displaying higher affinity for unmethylated
than for methylated capped RNA. IFIT1 tethers a species-specific protein complex consisting of other IFITs to RNA. Pulsed
stable isotope labelling with amino acids in cell culture coupled to mass spectrometry as well as in vitro competition assays
indicate that IFIT1 sequesters 29O-unmethylated capped RNA and thereby impairs binding of eukaryotic translation
initiation factors to 29O-unmethylated RNA template, which results in inhibition of translation. The specificity of IFIT1 for
29O-unmethylated RNA serves as potent antiviral mechanism against viruses lacking 29O-methyltransferase activity and at
the same time allows unperturbed progression of the antiviral program in infected cells.
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Introduction
Effective control of viral infection by host organisms requires
sensing of pathogens and activation of appropriate defence
mechanisms [1–3]. One component commonly sensed by the host
is viral genetic material, whether DNA delivered to the cytoplasm
through viral infection or viral RNA bearing motifs not commonly
found on eukaryotic RNAs [4,5]. Most cellular cytoplasmic RNAs
are single-stranded, and bear a 59monophosphate (rRNAs and
tRNAs), or an N7 methylated guanosine cap (mRNAs) linked via a
59-to-59 triphosphate bridge to the first base. In higher eukaryotes,
mRNA is further methylated at the 29O position of the first ribose
[6,7]. Viruses, in contrast, can form long double-stranded RNA
(dsRNA) and generate RNAs bearing 59triphosphosphates (PPP-
RNA) or RNAs lacking methylation [8–10]. All these distinct
features of viral as opposed to cellular RNAs have been shown to
activate the innate immune system and elicit synthesis of antiviral
cytokines including Type I interferons (IFN-a/b), which ultimately
restrict virus growth [11–14]. Among the proteins that sense viral
RNA and are linked to IFN-a/b synthesis are retinoic acid-inducible
gene I (RIG-I) and melanoma differentiation-associated gene 5
(Mda-5), which form the family of RIG-like receptors (RLRs) [5]. A
further set of host proteins appears to bind virus-derived RNAs to
directly inhibit virus production [8]. Several of these proteins are
highly expressed upon stimulation of cells with cytokines like IFN-a/
b and their antiviral effects become apparent only after binding to
virus-derived nucleic acid. Prominent examples for such proteins are
dsRNA binding proteins such as dsRNA-activated protein kinase R
and 29-59 oligoadenylate synthetase, and proteins that bind PPP-
RNA, like interferon-induced proteins with tetratricopeptide repeats
(IFIT) 1 and -5 [3,15,16]. Little is known about the repertoire of
cellular proteins that recognise unmethylated cap structures,
although replication of viruses with inactive RNA 29O methyltrans-
ferase is strongly inhibited by IFN-a/b in vitro and in vivo [11,15].
Some of this antiviral activity has been genetically linked to Ifit1 and
-2 in mice [17–19]. Here, we used an unbiased mass-spectrometry-
based approach to identify cellular proteins that bind to 59
unmethylated and methylated capped RNA, and explored their
contribution to antiviral host responses.
Results
Identification of human and mouse proteins that bind
capped RNA
To identify proteins that interact with 59 capped RNA we used
a proteomics approach based on affinity purification and mass
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spectrometry (AP-MS) [16]. RNA bearing terminal 59 hydroxyl
(OH-RNA), 59 triphosphate (PPP-RNA), an unmethylated cap
(CAP-RNA), a guanosine-N7 methylated cap (CAP0-RNA), or a
guanosine-N7 methylated cap and a ribose-29O methylated first
nucleotide (CAP1-RNA) was coupled to agarose beads. The beads
were then incubated with lysates of naı¨ve HeLa cells or HeLa cells
treated with IFN-a to increase the abundance of antiviral proteins
(Fig. 1a, Fig. S1). By employing liquid-chromatography coupled to
tandem mass spectrometry (LC-MS/MS) followed by quantitative
interaction proteomics analysis, we identified 528 proteins that
interacted with unmodified or RNA-coated beads (Fig. S2a, Table
S1). While a large number of proteins were equally well
represented in the bound fractions obtained with all RNAs (Fig.
S2a), 68 proteins were found to be significantly enriched in
samples recovered with 59modified RNA compared to OH-RNA
(Fig. S2b). As expected, the PPP-RNA binding proteins RIG-I
(DDX-58), the IFIT1, -2, -3 complex and IFIT5 were enriched in
PPP-RNA affinity purifications of IFN-a-treated HeLa cell lysate
(Fig. 1b), validating the approach and confirming previous data
[16]. Using unmethylated CAP-RNA as bait, we significantly
enriched for proteins known to associate with cellular capped
RNA (12 of 16 proteins) (Fig. 1c, Fig. S2b, Table S1). However, an
important feature of cellular mRNAs is methylation on the N7
position of the guanosine cap and the ribose-29O position of the
first nucleotide (CAP1). N7 methylation is known to increase the
affinity of the cap structure for proteins such as EIF4E and other
cap-binding proteins [6,7]. A methylation-dependent increase in
protein binding was also evident in our AP-MS analysis when
unmethylated CAP-RNA and methylated CAP1-RNA were used
as baits (16 vs. 27 identified proteins), as the latter captured a
higher number of significantly enriched proteins and, overall, these
were enriched to a greater degree, as measured by label-free
quantification (Fig. 1c–d, Table S1). Notably, we identified IFIT1,
-2 and -3 among the uncharacterised CAP-RNA binding proteins,
suggesting that the IFIT complex binds to RNA in a cap-
dependent manner (Fig. 1c). IFIT5, which shows 57.2%
aminoacid sequence identity and 75.6% similarity to IFIT1 and
has recently been shown to form a tight binding pocket that
specifically accommodates PPP-RNA [20], was not detected in
fractions that bound capped RNA. When we compared our AP-
MS dataset with transcriptome data of interferon-stimulated cells
[21], IFITs were the only interferon-induced proteins found to be
specifically enriched in CAP-RNA purifications, suggesting a
predominant role of IFITs in innate immune responses directed
against CAP-RNA (Fig. 1c, Fig. S2b). To analyse whether the set
of proteins that binds to 59modified RNA is conserved in other
species, we performed the same AP-MS analysis on lysates of naı¨ve
and IFN-a-treated mouse embryonic fibroblasts (MEFs) (Fig. S3a,
b, Table S2). Surprisingly, although PPP-RNA specifically
enriched for Ifit1, the abundance of Ifit2 and Ifit3 was not
increased (Fig. 1e). Instead we found enrichment of Ifit1c (also
known as Gm14446), an uncharacterised IFIT protein that is
strongly induced by IFN-a/b or virus infection (Fig. S4),
suggesting that the architecture of the murine IFIT complex
differs from that of its human counterpart. Significant enrichment
for Ifit1 and Ifit1c could also be achieved with unmethylated CAP-
RNA, but not with methylated CAP1-RNA, despite the fact that
the latter bait captured more proteins with higher enrichment
scores (Fig. 1f, g). We concluded from these analyses that, in both
human and mouse, the IFIT complex is the only IFN-induced
component that shows significant affinity for capped RNA.
IFIT1 is the only IFIT that binds capped RNA
Since human IFIT1, -2 and -3 associate with each other to form
a multiprotein complex, we wished to determine which of them
was responsible for tethering the IFIT complex to unmethylated
CAP-RNA. We overexpressed each of the IFIT proteins, tagged
with Renilla luciferase, in 293T cells and performed affinity
purifications using OH-RNA, PPP-RNA and CAP-RNA. Re-
markably, only human and murine IFIT1 were detected when
CAP-RNA was used as bait (Fig. 2a, b), suggesting that IFIT1
mediates binding of the IFIT complex to CAP-RNA. Consistent
with the MS analysis, IFIT5 exclusively bound to PPP-RNA but
not to CAP-RNA. To exclude contribution of cellular factors to
the interaction between IFIT1 and CAP-RNA we used recombi-
nant human IFIT proteins for RNA precipitations which
confirmed a direct interaction of IFIT1 with capped RNA
(Fig. 2c). A structure-based modelling approach using IFIT5
[20] as template suggested that the RNA-binding cavity of IFIT1
is ,700 A˚3 larger than that of IFIT5 (Fig. S5) – implying that
IFIT1 has slightly different RNA-binding properties. However, a
lysine at position 151 and an arginine at position 255 of IFIT1,
two residues involved in binding the terminal 59 triphosphate
group on PPP-RNA by IFIT5 and IFIT1 [20], were also required
for binding of IFIT1 to capped RNA (Fig. 2d), indicating an
overall similar mode of binding.
To provide additional evidence that binding of IFIT1 is indeed
responsible for associating the IFIT complex to CAP-RNA, we
performed AP-MS experiments on wild-type (Ifit1+/+) and mutant,
Ifit1-deficient (Ifit12/2) MEFs. The overall precipitation efficiency
was comparable in both cell types, as evidenced by equal
enrichment of the RNA-binding protein Syncrip and the cap-
binding protein Ncbp1 (Fig. 2e and Fig. S4b). Ifit1c was not
enriched in precipitates from Ifit12/2 MEFs, which is consistent
with the notion that the murine Ifit complex binds to CAP-RNA
through Ifit1. These results show that the specific binding
properties of IFIT1 are essential for recruitment of the human
and murine IFIT complexes to their RNA targets.
IFIT1 binding depends on the methylation status of the
RNA cap
To identify proteins that bind capped RNA in a methylation-
dependent manner we used unmethylated CAP-RNA and fully
Author Summary
Cellular messenger RNAs of higher eukaryotes are capped
with a methylated guanine and, in addition, methylated at
the 29O position of the first ribose. Viruses unable to
methylate their RNA at the 29O position of the cap and
viruses generating uncapped RNA with 59 triphosphate
groups are inhibited by an antiviral complex of different
IFIT proteins. How IFIT proteins restrict viruses lacking 29O
methylation at the RNA cap remained unclear. We used a
mass spectrometry-based approach to identify proteins
binding to capped RNA with different methylation states.
We found that IFIT1 directly binds to capped RNA and that
this binding was dependent on the methylation state of
the cap. Having identified IFIT1 as being central for
recognition of 29O-unmethylated viral RNA we further
examined the mode of action of IFITs in vitro and in vivo.
Our experiments clearly show that the antiviral mechanism
of IFIT1 is based on sequestration of viral RNA lacking cap
29O methylation, thereby selectively preventing translation
of viral RNA. Our data establish IFIT1 as a general sensor for
RNA 59 end structures and provide an important missing
link in our understanding of the antiviral activity of IFIT
proteins.
IFIT1 Sequesters 29O-Unmethylated Viral RNA
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Figure 1. Mass spectrometry-based identification of human and murine interactors of capped RNA. (a) Schematic depiction of the
experimental approach used for mass spectrometry (MS)-based identification of cellular RNA binding proteins. Biotinylated RNA with different 59 end
structures (OH, PPP, CAP, CAP0, CAP1) was coupled to streptavidin beads, and incubated with lysates obtained from cells that had been left
untreated or treated with 1000 U/ml IFN-a for 16 h. Bound proteins were denatured, alkylated and directly digested with trypsin. The resulting
peptides were subjected to shotgun liquid chromatography-tandem MS (LC-MS/MS). Three independent experiments were performed for each RNA
bait, and the data were analysed with the MaxQuant software [37] using the label-free quantification algorithm [38]. (b–d) Proteins obtained from
lysates of IFN-a-treated HeLa cells using the indicated biotinylated RNA baits were analysed by LC-MS/MS. Volcano plots show the degrees of
enrichment (ratio of label-free quantitation (LFQ) protein intensities; x-axis) and p-values (t-test; y-axis) by PPP-RNA (b), CAP-RNA (c), and CAP1-RNA
(d) baits as compared to OH-RNA. Significantly enriched interactors (see Materials and Methods) are separated by a hyperbolic curve (dotted line)
from background proteins (blue dots), known cap-binding proteins (dark-green), and proteins known to associate with capped RNA (light green).
Interferon-induced proteins [21] detected in the significantly enriched fractions (IFIT1-3 and 5, DDX58) are highlighted (red triangles). (e–g) As in (b–
d) but for lysates of IFN-a-treated mouse embryo fibroblasts (MEFs). The interferon-induced proteins Ifit1 and Ifit1c [42] in significantly enriched and
non-enriched fractions are highlighted.
doi:10.1371/journal.ppat.1003663.g001
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Figure 2. Human and mouse IFIT1 bind directly to unmethylated capped RNA. (a) Isolation of luciferase-tagged human IFIT (hIFIT) proteins
from transfected 293T cells with beads coated with 250 ng RNA bearing 59 OH, PPP or CAP. The graphs show luciferase activity after affinity
purification (AP) with PPP-RNA and CAP-RNA (normalized to OH-RNA) and the activity of 10% of the input lysates. (b) Data obtained (as in a) for
luciferase-tagged murine Ifit (mIfit) proteins affinity purified with PPP-RNA and CAP-RNA. (c) Recombinant His-tagged hIFIT1, -2, -3, and -5 were
incubated with beads only or beads coated with OH-RNA or CAP-RNA. Bound proteins were detected by western blotting. Input shows 1/10th of the
amount incubated with beads. (d) Purification of luciferase-tagged wild-type (WT) and hIFIT1 mutants with CAP-RNA-coated beads. The graphs show
luciferase activity after affinity purification and the activity of 10% of the input lysates. (e) Ratios of LFQ intensities of proteins identified by mass
spectrometry in precipitates of CAP-RNA vs. OH-RNA in IFN-a-treated MEFs from wild-type (Ifit1+/+, grey bars) and Ifit1-deficient (Ifit12/2, black bars)
C57BL/6 mice. Error bars indicate means (6SD) from three independent affinity purifications. Asterisks indicate ratios with negative values.
doi:10.1371/journal.ppat.1003663.g002
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methylated CAP1-RNA as baits with IFN-treated HeLa cell
lysates and quantified the captured proteins by LC-MS/MS. As
expected [6,7], most cellular proteins were significantly enriched in
the CAP1-RNA bound fraction (Fig. 3a, Fig. S2c). The most
notable exceptions were IFITs and the cellular 29O-methyltrans-
ferase FTSJD2, both of which clearly favoured CAP-RNA (Fig. 3a,
Fig. S2c and Fig. 1 c, d and f, g). We confirmed the MS data by a
series of RNA precipitations followed by western blotting for
endogenous proteins. Proteins associating to RNA in a 59
independent manner, such as ILF3, precipitated similarly well
regardless of the RNA used (Fig. 3b). Cap N7 methylation
increased the association of EIF4E to RNA and methylation of the
29O position did not impair precipitation efficiency. In accordance
with the MS results, IFIT1 bound well to unmethylated CAP-
RNA and CAP0-RNA (N7 methylated cap) but revealed reduced
binding to CAP1-RNA (N7 methylated cap and 29O methylated
first ribos).
We next tested the contributions of individual cap methylation
sites to IFIT1 binding. To this end, we measured binding of
luciferase-tagged human and murine IFIT1 with either CAP-,
CAP0- or CAP1-RNA. The unmethylated CAP-RNA bait
captured more human or murine IFIT1 than either of the
methylated RNAs (Fig. 3c). Furthermore, the analysis suggested
that N7 methylation on the cap and 29O methylation of the first
ribose both contributed to the reduced binding of IFIT1 to RNA.
Similarly, the precipitation efficiency of recombinant human and
murine IFIT1 was reduced when capped in vitro transcribed RNAs
were enzymatically methylated at the N7 and 29O position (Fig. 3d)
or when chemically synthesised RNAs with the same modifications
were used (Fig. 3e). This was in contrast to EIF4E that showed
prominent binding when CAP0- or CAP1-RNA was used (Fig. 3d,
e). Collectively, these data suggest that human and murine IFIT1
have the capability to directly sense the methylation state of
capped RNA.
Antiviral activity of IFIT1 against 29O methyltransferase-
deficient viruses
Having established that IFIT1 binds directly to capped RNA
and that methylation on the 29O position of the first ribose
markedly reduces binding, we tested the impact of IFIT1 on virus
replication. Probably as a result of evolutionary pressure, most
viruses that infect higher eukaryotes have evolved mechanisms to
generate RNA that is methylated on both the N7 position of the
guanosine cap and the 29O position of the first ribose [9]. We
therefore used wild-type human coronavirus (HCoV) 229E (229E-
WT), which generates CAP1-RNA, and a mutant variant that has
a single amino acid substitution (D129A) in the viral 29O
methyltransferase that is part of non-structural protein 16 (229E-
DA), and consequently only produces CAP0-RNA [11]. IFN-a-
treated HeLa cells infected with the 229E-DA mutant expressed
significantly reduced levels of viral RNA and protein relative to
those exposed to 229E-WT (Fig. 4a, b). Moreover, this effect was
strictly dependent on IFIT1, since the two viruses replicated
equally well in HeLa cells treated with siRNA against IFIT1
(Fig. 4a, b). Similar effects were observed in an analogous mouse
model. Thus, when IFN-a treated macrophages (MWs) from
C57BL/6 (Ifit +/+) mice were infected with a wild-type murine
coronavirus (mouse hepatitis virus strain A59; MHV-WT) and a
mutant strain carrying the equivalent amino acid substitution
(D130A) in its 29O methyltransferase [11,17] (MHV-DA), the
latter produced 100-fold less viral RNA and comparably reduced
levels of viral protein (Fig. 4c, d). In contrast, when Ifit1-deficient
MWs were infected, no significant virus-dependent differences
were observed, again pointing to a critical role for Ifit1 in
restricting replication of MHV-DA. Note that the presence of Ifit1
itself did not increase IFN-a/b production (Fig. S6), suggesting a
direct antiviral effect of Ifit1. We next assessed the impact of Ifit1
on virus growth in vivo. MHV-WT grew to high titres in the spleens
of infected Ifit1+/+ mice, whereas no viral replication could be
detected upon infection with MHV-DA (Fig. 4e). In agreement
with the in vitro data, growth of MHV-DA was partially restored in
Ifit1-deficient animals. These data suggest that IFIT1 has a central
role in restraining the growth of 29O methyltransferase-deficient
coronaviruses in vitro and in vivo, which is compatible with the
greater affinity of IFIT1 for non-29O-methylated RNA cap
structures. The data further imply that this role is conserved in
mouse and human.
IFIT1 specifically regulates the translation of 29O
unmethylated capped viral RNA
RNA capping is essential for a variety of cellular functions. The
presence of a 59 cap regulates mRNA export from the nucleus,
protects RNAs from degradation and is necessary for efficient
translation [7,22]. An involvement of IFIT1 in nuclear-cytoplas-
mic transport is unlikely, given the exclusively cytoplasmic
localisation of IFIT proteins and their negative effect on
coronaviruses, which replicate in the cytoplasm. We therefore
measured the stability of the RNAs generated by MHV-WT or
MHV-DA in MWs that had been stimulated with IFN-a. Since
MHV-WT replicates significantly better than the mutant virus, we
blocked virus replication by adding cycloheximide (CHX) shortly
after infecting MWs with the two viruses (Fig. 5a). CHX inhibits de
novo synthesis of the viral polymerase, a prerequisite for
transcription of viral RNA and thereby allows to normalise for
viral transcripts in coronavirus infected cells. The abundance of
viral transcripts 4 h and 8 h after infection was indistinguishable in
CHX treated cells infected with MHV-WT and MHV-DA
(Fig. 5b), suggesting that 29O methylation of the first ribose does
not affect the stability of the viral RNA within the timeframe of
this experiment.
Many cellular antiviral defence mechanisms generally block
translation of mRNA, thereby also severely inhibiting virus
growth. To assess the global impact of Ifit1 on the translation
machinery, we used pulsed stable isotope labelling in cell culture
(SILAC) [23]. In pulsed SILAC, unlabelled cells are transferred to
SILAC growth medium containing 13C- and 15N-labelled arginine
(Arg10) and lysine (Lys8). Newly synthesized proteins incorporate
the heavy label and pre-existing proteins remain in the light form,
which allows to measure relative changes in the translation of
individual proteins, regardless of the absolute amount of RNA
present. We pulsed Ifit1+/+ and Ifit12/2 MWs infected for 5K h
with either MHV-WT or MHV-DA for 2 h with SILAC medium
(Fig. 5c) and analysed infected cells by whole-proteome shotgun
LC-MS/MS. We could reliably quantify 721 proteins in terms of
heavy/light ratios in all three biological replicates tested. Heavy/
light ratios of cellular proteins were comparable in Ifit1+/+ and
Ifit12/2 MWs, irrespective of the virus used for infection (Fig. 5d,
boxes), suggesting that neither the presence of Ifit1 nor infection
with MHV-DA affected the overall rate of translation in the cells.
The expression profiles of individual proteins known to be
important in innate immune responses against viruses, such as
the pattern recognition receptor RIG-I (DDX58), signalling
molecules (STAT1, -2, -3), interferon-induced proteins (Ifi205b,
Ifi35, Gvin1) and components of the major histocompatibility
complex (H2-K1, H2-D1, Cd74), were similar in both cell types
infected with either virus (Fig. S7). However, translation of viral
nucleocapsid and membrane proteins was selectively reduced in
Ifit1+/+ MWs infected with MHV-DA (Fig. 5d and Fig. S7).
IFIT1 Sequesters 29O-Unmethylated Viral RNA
PLOS Pathogens | www.plospathogens.org 5 October 2013 | Volume 9 | Issue 10 | e1003663
Variation in large datasets can be best evaluated by principal-
component analysis, which computes the variable with the greatest
effect in a given dataset. This analysis revealed that Ifit1+/+ MWs
infected with MHV-DA showed the highest variation (Component
1 accounting for 55.9% of variation) as compared to all other
conditions tested (Fig. 5e), and among all identified proteins,
MHV proteins were mainly responsible for this variation (Fig. 5f).
Taken together, these data indicate that synthesis of proteins
encoded by viral RNAs lacking 29O methylation on the first ribose
is specifically inhibited by IFIT1. Expression of proteins encoded
by fully methylated RNA, such as cellular mRNA or 29O
methylated viral RNA, is not affected by the activity of IFIT1.
IFIT1 and translation factors compete for mRNA
templates
Translation of cellular capped mRNA requires binding of the
cap-binding protein EIF4E, which has a high affinity for
Figure 3. IFIT1 binds capped RNA in a methylation state-dependent manner. (a) Ratio of LFQ intensities of proteins identified by LC-MS/MS
as significantly enriched in CAP1-RNA relative to CAP-RNA affinity purifications from IFN-treated HeLa cells, after filtering against the set of proteins
that showed enrichment relative to 59 OH-RNA(see Fig. S2b). Error bars indicate means (6SD) from three independent affinity purifications. (b)
Precipitation of endogenous proteins from lysates of IFN-a treated HeLa cells with biotinylated RNA bearing 59 OH, PPP, CAP, CAP0 or CAP1
structures. Human IFIT1 (hIFIT1), EIF4E and ILF3 in precipitates were detected by western blotting. Input shows 1/10th (mIFIT1, EIF4E) and 1/30th
(hIFIT1) of the amount incubated with beads. (c) Affinity purification of luciferase-tagged human (hIFIT1) and murine (mIfit1) IFIT1 expressed in 293T
cells on beads bearing 59 OH, CAP, CAP0, or CAP1 RNA. (d) Binding of recombinant IFIT1 to capped RNAs. As in (c), but RNA-coated beads were
incubated with recombinant His-tagged mouse Ifit1 (His-mIfit1), human His-hIFIT1 or human His-EIF4E and bound protein was quantified by western
blotting. (e) Binding of recombinant His-tagged hIFIT1 and EIF4E to chemically synthesized, biotinylated RNA oligomers. Synthetic triphosphorylated
RNAs with (CAP1) or without (CAP0) 29O-methyl group on the first ribose were capped in vitro using recombinant vaccinia virus capping enzyme (see
Materials and Methods). As control we used a synthetic RNA harbouring a 59 hydroxyl group (OH). Synthetic RNAs were coupled to beads, incubated
with recombinant proteins and bound proteins detected by western blotting. Input shows 1/10th of the amount incubated with beads.
doi:10.1371/journal.ppat.1003663.g003
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methylated cap structures [7,22]. Therefore, we tested whether
IFIT1 could compete with EIF4E for binding to RNA template.
We coupled limiting amounts of unmethylated CAP-RNA, N7-
methylated CAP0-RNA and fully methylated CAP1-RNA to
beads and tested whether the binding ability of recombinant
EIF4E is altered by the presence of recombinant IFIT1. When we
used CAP-RNA or CAP0-RNA, EIF4E binding to the beads was
reduced by addition of IFIT1, suggesting that the two proteins
compete for the RNA target (Fig. 6a). In contrast, when
methylated CAP1-RNA was used the amount of EIF4E recovered
was not affected by the presence of IFIT1. Competition between
Eif4e and Ifit1 for capped RNA was also seen when total lysates of
IFN-a-stimulated MEFs were used as inputs for experiments.
Unmethylated CAP-RNA captured considerably more Eif4e from
Figure 4. IFIT1 inhibits viral RNA and protein synthesis in cells infected with 29Omethyltransferase-deficient coronavirus. (a–b) HeLa
cells were cotransfected for 48 h with an expression construct for the HCoV-229E receptor, human aminopeptidase N, and siRNAs targeting IFIT1 or
the green fluorescent protein (GFP). Cells were then treated with 20 U IFN-a and infected with wild-type HCoV-229E (229E-WT; grey bars) or the 29O
methyltransferase-deficient HCoV-229E (D129A) mutant (229E-DA; red bars). Total RNA and protein were harvested 24 h post infection and analysed
by quantitative RT-PCR (a) and western blotting (b), respectively. Quantitative RT-PCR data are from one of three representative experiments showing
means 6SD for HCoV-229E nucleoprotein (229E-N) RNA after normalization to cyclin B (CycB) mRNA. (c–d) Bone marrow-derived macrophages (Mw)
derived from C57BL/6 (Ifit1+/+) and Ifit1-deficient (Ifit12/2) mice were treated or not with 50 U of IFN-a for 2 h and infected with wild-type MHV (WT;
grey bars) or 29O methyltransferase-deficient MHV (DA; red bars). RNA and protein were harvested 8 h post infection and analysed by quantitative RT-
PCR (c) and western blotting (d). Quantitative RT-PCR results are from one of three representative experiments, showing means 6SD for MHV
nucleoprotein (MHV-N) RNA after normalization to the TATA-binding protein (TBP) mRNA. (e) Ifit1+/+ and Ifit12/2mice were infected intraperitoneally
with 5,000 plaque-forming units of MHV WT (grey bars) or DA (red bars). Viral titers in the spleens of 12 mice per condition were measured 48 h after
infection. Data are shown as Tukey box-whisker plots (ND, not detectable; outlier indicated as black dot).
doi:10.1371/journal.ppat.1003663.g004
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Figure 5. IFIT1 specifically blocks translation of 29-O-unmethylated capped viral RNA. (a) Experimental design used to assess the stability
of MHV RNA in infected cells. Bone marrow-derived macrophages (Mw) from C57/BL6 mice were treated with 50 U of IFN-a for 2 h prior to infection
with wild-type MHV (WT) or 29O methyltransferase-deficient MHV (DA) at 4uC for 1 h. Directly after infection, cells were treated with 100 mg/ml
cycloheximide (CHX) or DMSO. Total RNA was harvested at 0, 4, and 8 h post infection and analysed by quantitative RT-PCR. (b) MHV nucleoprotein
(MHV-N) RNA in cells infected with MHV WT (grey) or DA mutant (red), treated with DMSO (solid lines) or CHX (dashed lines). Data from one
representative experiment of three are depicted, showing means6SD after normalization to a known amount of in vitro transcribed Renilla luciferase
RNA (Ren) added to cell lysates. (c) Experimental design for pulsed SILAC coupled to mass spectrometry to determine relative changes in protein
translation during infection. Macrophages from C75/BL6 (Ifit1+/+) and Ifit1-deficient (Ifit12/2) mice grown in normal growth medium containing light
(L) amino acids were infected at 4uC for 1 h with wild-type MHV (WT) or 29O methyltransferase-deficient MHV (DA). Five hours post infection cells
were incubated with starvation medium (lacking Lys and Arg) for 30 min, then SILAC medium containing heavy (H) labelled amino acids (Lys8, Arg10)
was added, and 2 h later total protein lysate was prepared and subjected to LC-MS/MS analysis. (d) Translation rates for 721 cellular proteins, as
determined by heavy (H) to light (L) ratios from LC-MS/MS, were plotted as box-whisker plots (whiskers from 10th to 90th percentile). Individual ratios
for the MHV nucleoprotein (MHV-N) and membrane protein (MHV-M) in WT- (grey) and DA-infected (red) Ifit1+/+ (circles) and Ifit12/2 (triangles)
macrophages are plotted separately. Data are from three independent experiments. (e,f) Principal Component Analysis based on valid H/L ratios of
all measurements from (d) showing clustering of the individual samples of the entire dataset (e). Panel (f) shows all proteins plotted for their
contribution to the variation in components 1 and 2. MHV proteins are indicated in blue.
doi:10.1371/journal.ppat.1003663.g005
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lysates of IFN-a treated Ifit12/2 MEFs than from lysates of Ifit1+/+
MEFs (Fig. 6b). This difference disappeared when methylated
CAP1-RNA was used as bait (Fig. 6b). We therefore conclude that
IFIT1 competes with cellular translation initiation factors for
mRNA, thereby selectively regulating translation based on the 59
methylation status of the RNA templates present (Fig. 6c).
Discussion
We previously identified IFIT1 as a nucleic acid-binding protein
that recognises the 59triphosphosphate present on genomes and
transcripts of most negative-strand RNA viruses [16]. Here we
show that, in addition, IFIT1 binds mRNAs that lack 29O
methylation on the first ribose, such as those produced by RNA
viruses that replicate in the cytoplasm and are deficient in RNA
cap-specific ribose-29-O methyltransferase activity. This suggests
that IFIT1 has a unique ability to recognize 59 RNA modifications
that are present on viral nucleic acids. Co-purification experiments
with human IFIT proteins clearly show formation of a multi-
protein complex comprising IFIT1, -2 and -3. Overexpression of
single IFIT proteins, including IFIT1, only marginally affects viral
growth [16,17], suggesting that the cooperative action of IFIT
proteins is required for full antiviral action. This is supported by
loss-of-function experiments in cell culture and in vivo that show a
requirement for Ifit2, which by itself does not bind CAP-RNA, to
restrict viruses lacking 29O methyltransferase activity [17,18].
IFIT2 is known to bind to components of the cytoskeleton [24],
which could allow intracellular trafficking of the IFIT complex to
its sites of action. While some IFITs possess conserved biological
activities in different species, e.g. human and murine IFIT1 which
bind to PPP-RNA and unmethylated CAP-RNA, others appear to
have evolved in a species-specific manner. We showed here that
the yet uncharacterised murine interferon-induced Ifit1c binds to
RNA-coated beads in an Ifit1-dependent manner, and we
therefore propose that a corresponding Ifit complex with a
different protein composition exists in mice.
Residues previously identified to be important for binding of the
triphosphate moiety are also required for binding of unmethylated
CAP-RNA by IFIT1, suggesting a conserved mechanism of RNA
binding. In this context it is of interest to note that crystallographic
analysis indicates that PPP-RNA binding to IFIT5, which shows
high similarity to IFIT1, occurs in a fashion that is reminiscent of
CAP-RNA binding by cap-binding proteins, in that the first two
nucleotides are stacked by an aromatic phenylalanine [20].
However, the higher affinity of IFIT1 for unmethylated relative
to fully methylated capped RNA is unusual among cellular
Figure 6. Competition between IFIT1 and translation factor EIF4E for mRNA templates. (a) Recovery of recombinant human EIF4E based
on RNA affinity binding in the presence or absence of IFIT1. Streptavidin beads were coupled to 250 ng of the indicated RNA and mixed with 5 mg of
recombinant His-tagged hIFIT1 and/or His-tagged EIF4E, as indicated. Bound proteins were analysed by western blotting with antibodies directed
against the His-tag. (b) As in (a), except that RNA-coated beads were incubated with lysates of interferon-treated Ifit1+/+ and Ifit12/2 mouse embryo
fibroblasts. Bound proteins were analysed by western blotting with antibodies directed against murine Eif4e and mIfit1. (c) Proposed model for IFIT1-
mediated translational inhibition of 29O-unmethylated viral RNA. Capped and 29O-methylated cellular and viral RNA is bound by EIF4E to initiate
translation. Viral mRNA lacking 29O methylation at the first ribose is recognized by IFIT1 which prevents binding of cellular factors required for
efficient translation. The model is based on data presented here and elsewhere [16,17,19,20].
doi:10.1371/journal.ppat.1003663.g006
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proteins since 59 methylation has so far been reported to increase
the affinity of cellular proteins for RNA [7], a notion clearly
supported by our RNA AP-MS data. Like its specific antiviral
activity, this property of IFIT1 may only become apparent during
infections with viruses that produce non-methylated RNA 59 ends
[25,26]. We propose that IFIT1 acts as a molecular switch that
allows selective translation based on the 59 methylation state of the
mRNA. The phenomenon of translational control by IFIT1 based
on its differential affinity for the capped RNA is reminiscent of the
4E homologous protein (4EHP) in Drosophila and mice, which
has been found to control translation by competing with EIF4E for
the RNA cap structure, thereby regulating development-specific
gene expression [27,28]. Similarly, in our hands, IFIT1 does not
associate directly with the translation machinery ([16] and data
not shown), which again suggests that it perturbs translation
through sequestration of viral RNA. Such a model is consistent
with the high expression levels of IFIT proteins resulting from
infections with viruses or treatment with IFN-a/b.
Rather than mediating general inhibition of translation, IFIT1
shows high selectivity for mRNAs that lack 59 methylation. This is
supported by pulsed SILAC experiments showing specific, IFIT1-
dependent inhibition of translation of capped RNAs lacking 29O
methylation at the first ribose, such as those generated by MHV
and HCoV mutants expressing inactive 29O methyltransferase.
Lower eukaryotes and viruses that infect them lack 29O
methylated CAP RNA [29–31], and the latter should be
susceptible to the antiviral activity of IFITs. Consequently, the
IFIT defence system is likely to contribute to a species barrier that
puts selective pressure on viruses to generate 59 methylated RNA.
Our data provide a mechanistic rationale for why most viruses
make considerable effort and dedicate part of their coding capacity
to produce genomic and subgenomic RNAs with 59-terminal ends
that perfectly mimic those of cellular mRNAs, including fully
methylated 59-cap structures [9,31–33]. Other viruses have
evolved specific mechanisms to hide their uncapped/unmethy-
lated 59 ends, for example, by covalent binding of viral proteins to
the 59 end of viral RNAs and use of alternative strategies for
translation initiation, thereby escaping IFIT1-based surveillance,
which is centred on RNA 59 end structures. Despite these viral
strategies to generate host-like mRNAs, IFIT1 remains active
against viruses that generate 59 triphosphate RNA, most likely
through translation-independent mechanisms. The ability of
IFIT1 to target viral RNAs selectively allows the cell to specifically
fight virus infections while pursuing an antiviral program aimed at
destroying the intruding pathogen.
Materials and Methods
Ethics statement
All animal experiments were performed in accordance with
Swiss federal legislation on animal protection and with the
approval of the Animal Studies Committee of the Cantonal
Veterinary Office (St. Gallen, Switzerland), license nr. SG 11/03.
Reagents, cells and viruses
Interferon-a (IFN-a A/D) was a kind gift from Peter Sta¨heli.
Expression constructs for human and murine IFIT proteins
[16,20] and the human aminopeptidase N (APN) were described
previously. Products tagged with Renilla luciferase were expressed
from constructs obtained by Gateway cloning into pCDNA-REN-
NT-GW (a kind gift from Albrecht v. Brunn). For expression in
bacteria, human EIF4E cDNA was cloned into pETG10A-GW
[16]. Recombinant IFIT proteins and human EIF4E were
expressed in E. coli and purified using HisPur Ni-NTA resin
(Thermo Scientific). Streptavidin-agarose beads were obtained
from Novagen. Polyclonal antibodies directed against human and
mouse IFIT1 were described previously [16]. The antibody
against MHV nucleoprotein (MHV-N556) was kindly donated by
Stuart Siddell. Primary antibodies against ILF-3 (Sigma;
HPA001897), the nucleoprotein of HCoV-229E (Ingenasa; mAb
1H11) and EIF4E (Cell Signaling; C46H6) were obtained from
commercial sources. For western blot analysis we used horseradish
peroxidase (HRP)-coupled antibodies specific for actin (Santa
Cruz; sc-47778), the His-tag (Santa Cruz; sc-8036) or the c-Myc-
tag (Roche; 1667149), and HRP-coupled secondary antibodies
(Jackson ImmunoResearch). All cell lines used (293T, HeLa, Vero-
E6, Huh7, L929, 17Clone1, and Ifit1+/+ and Ifit12/2 mouse
embryonic fibroblasts) were described previously [11,16], and
were maintained in DMEM (PAA Laboratories) containing 10%
fetal calf serum (PAA Laboratories) and antibiotics (100 U/ml
penicillin, 100 mg/ml streptomycin). DMEM medium containing
antibiotics, 10 mM L-glutamine, 10% dialyzed fetal calf serum
(PAA Laboratories) and 84 mg/L 13C6
15N4 L-arginine and
146 mg/L 13C6
15N2 lysine (Cambridge Isotope Laboratories) was
used for SILAC experiments. Murine bone marrow-derived
macrophages were generated in vitro by cultivating bone marrow
from mouse femur and tibia in DMEM supplemented with 10%
(v/v) fetal calf serum, 5% (v/v) horse serum, 10 mM HEPES
pH 7.4, 1 mM sodium pyruvate, 10 mM L-glutamine and 20%
(v/v) L929 cell-conditioned medium (containing macrophage
colony-stimulating factor) for 6 days. Reagents for transfection
with plasmid DNA (Nanofectin) or siRNA duplexes (siRNA Prime)
were obtained from PAA Laboratories. Wild-type and 29-O-
methyltransferase-deficient recombinant coronaviruses [mouse
hepatitis virus strain A59 (MHV) and human coronavirus 229E
(HCoV-229E) [11]], Sendai virus, RVFV Clone13 [34] and VSV-
M2 (mutant VSV with the M51R substitution in the matrix
protein) [35] have been described previously. Duplex siRNAs




GG)dAdG] and the green fluorescent protein [sense: 59 r(AAG-
CAGCACGACUUCUUCAAGU)dT 39; antisense 59 r(CUU-
GAAGAAGUCGUGCUGCUUU)dT 39] were synthesized by the
Core Facility at the MPI of Biochemistry.
Capping and methylation of in vitro transcribed RNA
Triphosphorylated PPP-RNA was synthesized by in vitro
transcription with SP6 or T7 polymerase (RiboMAX Large Scale
RNA Production Systems; Promega), in the presence or absence of
biotin-16-UTP (Enzo), from plasmids encoding antisense 7SK
RNA (7SK-as) [13] or Renilla luciferase (pRL-SV40; Promega),
and purified by ammonium-acetate isopropanol precipitation.
Aliquots of PPP-RNA were then mock-treated, dephosphorylated
with alkaline phosphatase (FastAP; Fermentas), or modified with
different 59 cap structures using the ScriptCap 29-O-Methyltrans-
ferase and m7G Capping System (CellScript) according to the
manufacturer’s instructions. Briefly, 20-mg samples of RNA were
heat-denatured at 65uC for 5 min, cooled on ice, then incubated
with ScriptCap Buffer in the presence of 500 mM GTP, 100 mM
SAM, 100 U 29-O-methyltransferase (VP39), 10 U Vaccinia
Capping Enzyme (VCE) and 40 U RNase inhibitor for 1 h at
37uC. Capped RNAs were further treated with FastAP to
dephosphorylate any residual PPP-RNA, and then column-
purified using the NucleoSpin RNA II kit (Macherey-Nagel). To
add radioactively labelled methyl groups to in vitro transcribed
RNA, 500 ng of each RNA was incubated with 100 U 29-O-
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methyltransferase or 10 U of VCE in 0.5 mM S-adenosylmethi-
onine and 1.4 mM S-[3H-methyl]-adenosylmethionine (78 Ci/
mmol; Perkin-Elmer) for 1 h at 37uC. Reactions were purified on
SigmaSpin Post-Reaction Clean-Up columns (Sigma) and eluates
were mixed with 2 ml Ultima Gold scintillation fluid for
measurement of 3H incorporation with a Packard Tri-Carb liquid
scintillation counter (Perkin Elmer).
Generation and capping of chemically synthesized RNA
oligomers
Capped m7Gppp-oligoribonucleotides matching the first 22
nucleotides of the 59 untranslated region of Severe Acute
Respiratory Syndrome Coronavirus HKU-39849 were prepared
by adding N7-methylated cap structures to chemically synthesized
RNA oligomers with a 39-terminal C6 amino linker. A tripho-
sphorylated RNA oligomer [PPP-r(AUAUUAGGUUUUUAC-
CUACCC)-NH2) and a corresponding 29O-ribose methylated
RNA-oligomer [PPP-r(AmUAUUAGGUUUUUACCUACCC)-
NH2] were ordered from ChemGenes Corporation (Wilmington,
MA, USA) and capped as described above using the m7G
Capping System (CellScript). Capped RNA oligomers were then
HPLC-purified, biotinylated with biotin-N-hydroxysuccinimide
ester (Epicentre) according to the manufacturer’s instructions and
again HPLC-purified. As control we used a corresponding 39-
terminal biotinylated and HPLC-purified oligoribonucleotide
harbouring a 59 hydroxyl group [OH-r(AUAUUAG-
GUUUUUACCUACCCU)-biotin].
Identification and quantitation of RNA-binding proteins
For quantitative purification of RNA-binding proteins, strepta-
vidin affinity resin was first incubated with 1-mg aliquots of biotin-
labelled OH-RNA, PPP-RNA, CAP-RNA, CAP0-RNA or CAP1-
RNA (all 7SK-antisense) in TAP buffer [50 mM Tris pH 7.5,
100 mM NaCl, 5% (v/v) glycerol, 0.2% (v/v) Nonidet-P40,
1.5 mM MgCl2 and protease inhibitor cocktail (EDTA-free,
cOmplete; Roche)] in the presence of 40 U RNase inhibitor
(Fermentas) for 60 min at 4uC on a rotary wheel. Control or
RNA-coated beads were then incubated with 2-mg samples of
HeLa cell lysate for 60 min, washed three times with TAP buffer,
and twice with TAP buffer lacking Nonidet-P40 to remove
residual detergent. Three independent affinity purifications were
performed for each RNA. Bound proteins were dentatured by
incubation in 6 M urea-2 M thiourea with 1 mM DTT (Sigma)
for 30 min and alkylated with 5.5 mM iodoacetamide (Sigma) for
20 min. After digestion with 1 mg LysC (WAKO Chemicals USA)
at room temperature for 3 h, the suspension was diluted in 50 mM
ammonium bicarbonate buffer (pH 8). The beads were removed
by filtration through 96-well multiscreen filter plates (Millipore,
MSBVN1210), and the protein solution was digested with trypsin
(Promega) overnight at room temperature. Peptides were purified
on stage tips with three C18 Empore filter discs (3M) and analyzed
by mass spectrometry as described previously [36]. Briefly,
peptides were eluted from stage tips and separated on a C18
reversed-phase column (Reprosil-Pur 120 C18-AQ, 3 mM,
15060.075 mm; Dr. Maisch) by applying a 5% to 30%
acetonitrile gradient in 0.5% acetic acid at a flow rate of
250 nl/min over a period of 95 min, using an EASY-nanoLC
system (Proxeon Biosystems). The nanoLC system was directly
coupled to the electrospray ion source of an LTQ-Orbitrap XL
mass spectrometer (Thermo Fisher Scientific) operated in a data
dependent mode with a full scan in the Orbitrap cell at a
resolution of 60,000 with concomitant isolation and fragmentation
of the ten most abundant ions in the linear ion trap.
Affinity purification of luciferase-tagged and
recombinant proteins
N-terminally Renilla luciferase-tagged proteins were transiently
expressed in 293T cells. Three micrograms of each construct were
transfected into 66106 cells using 9.6 ml nanofectin (PAA
Laboratories) in 10-cm dishes according to the manufacturer’s
instructions. After 24 h, the medium was removed, and cells were
lysed in ice-cold TAP lysis buffer. An aliquot (10%) of the lysate
was removed to determine input luciferase activity. The rest was
added to streptavidin-agarose beads coated with 250 ng of RNA
as described above, and incubated on a rotary wheel at 4uC for
60 min. Beads were washed three times and resuspended in 50 ml
TAP buffer. Luciferase activities present in the suspension and in
the input lysate were assayed in Renilla reaction buffer (100 mM
K3PO4, 500 mM NaCl, 1 mM EDTA, 25 mM thiourea)
containing 10 mM coelenterazine as substrate. The reactions were
performed in triplicate and results were quantified using an
Infinite 200 PRO series microplate reader (Tecan). For affinity
purification of recombinant proteins with different RNAs, 50 to
250 ng of biotinylated RNA were coupled to streptavidin-agarose
beads for 60 min at 4uC. Beads were washed three times with TAP
buffer and incubated with recombinant His-tagged proteins for
60 min at 4uC. After three washes beads were boiled in Laemmli
buffer for 10 min at 95uC and subjected to SDS-PAGE and
Western Blot analysis.
Real-time RT-PCR
Total RNA was isolated using the NucleoSpin RNA II kit
(Macherey-Nagel), including on-column DNase digestion, and 200
to 500 ng of RNA was reverse transcribed with the RevertAid H
Minus First Strand cDNA Synthesis Kit (Fermentas). RNA levels
were then quantified by real-time RT-PCR using the QuantiTect
SYBR Green RT-PCR kit (Qiagen) and a CFX96 Touch Real-
Time PCR Detection System (BioRad). Each cycle consisted of
15 sec at 95uC, 30 sec at 50uC and 30 sec at 72uC, followed by
melting curve analysis. Primer sequences were as follows: Renilla




GACTCCTATGAC-39 and 59- CAAGTTTACAGCCAA-
GATTCA-39), mIFN-b (59-ATGGTGGTCCGAGCAGAGAT-
39 and 59-CCACCACTCATTCTGAGGCA-39), MHV-N (59-
GCCTCGCCAAAAGAGGACT-39 and 59- GGGCCTCTC-
TTTCCAAAACAC-39), 229E-N (59-CAGTCAAATGGGCT-
GATGCA-39 and 59- AAAGGGCTATAAAGAGAATAAGG-
TATTCT-39), mIfit1 (59- CCATAGCGGAGGTGAATATC-39
and 59- GGCAGGACAATGTGCAAGAA-39), mIfit1c (59-AAT-
CAGAAGAGGCAGCCATC-39 and 59-CATGGCTTCACT-
TGTGTTCC-39), mIfit2 (59-TCAGCACCTGCTTCATCCAA-
39 and 59-CACCTTCGGTATGGCAACTT-39), and mIfit3 (59-
GCTGCGAGGTCTTCAGACTT-39 and 59-TGGTCATGT-
GCCGTTACAGG-39).
Virus infection experiments in cell culture and in vivo
C57BL/6 mice were obtained from Charles River Laboratories
(Sulzfeld, Germany), and Ifit12/2 mice have been described
[16,17]. Mice were maintained in individually ventilated cages and
used at 6 to 9 weeks of age. All animal experiments were
performed in accordance with Swiss federal legislation on animal
protection and with the approval of the Animal Studies
Committee of the Cantonal Veterinary Office (St. Gallen,
Switzerland). Wild-type and Ifit12/2 mice (kindly provided by
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Michael Diamond) were injected intraperitoneally with 5,000
plaque-forming units of MHV. Virus titers in samples of spleens
removed and frozen 48 h post infection were assessed by standard
plaque assay on L929 cells. Bone marrow-derived macrophages or
mouse embryo fibroblasts (1 to 56105 cells) were treated or not
with IFN-a and infected with the indicated viruses at a multiplicity
of infection (MOI) of 5. For synchronised infection, cells were
infected with virus on ice and pre-warmed DMEM growth
medium was added 1 h later. To quantify the effects of siRNA-
mediated knockdown of IFIT1, aliquots of 105 HeLa cells that had
been transfected for 48 h with 15 pmol siRNA and 500 ng
expression plasmid for human APN using the siRNA Prime
reagent (PAA Laboratories) according to the manufacturer’s
instructions, were pretreated with IFN-a as indicated and infected
with HCoV-229E at an MOI of 1 for 24 h.
Pulsed SILAC and mass spectrometry
For pulsed SILAC, mouse macrophages labelled with heavy
isotopes (see above) were lysed in SDS lysis buffer (50 mM Tris
pH 7.5, 4% sodium dodecyl sulfate). The lysate was then heated
for 5 min at 95uC, sonicated for 15 min with a Bioruptor
(Diagenode) and centrifuged for 5 min at 16,0006 g at room
temperature. Protein concentration was determined by Lowry
assay (DC Protein Assay, BioRAD), and 50-mg aliquots were
reduced with 10 mM DTT for 30 min, alkylated with 55 mM
IAA for 20 min at room temperature, and precipitated with 80%
acetone for 3 h at 220uC. After centrifugation for 15 min at
16,0006g at 4uC, pellets were washed with 80% acetone, dried for
30 min at room temperature and dissolved in 6 M urea-2 M
thiourea. Proteins were digested with LysC and trypsin at room
temperature and peptides were purified on stage tips and analysed
by LC-MS/MS using a Easy nano LC system coupled to a Q
Exactive mass spectrometer (Thermo Fisher Scientific). Peptide
separation was achieved on a C18-reversed phase column
(Reprosil-Pur 120 C18-AQ, 1.9 mM, 20060.075 mm; Dr. Maisch)
using a 95-min linear gradient of 2 to 30% acetonitrile in 0.1%
formic acid. The mass spectrometer was set up to run a Top10
method, with a full scan followed by isolation, HCD fragmentation
and detection of the ten most abundant ions per scan in the
Orbitrap cell.
Bioinformatic analysis
Raw mass-spectrometry data were processed with MaxQuant
software versions 1.2.7.4 and version 1.3.0.5 [37] using the built-in
Andromeda search engine to search against human and mouse
proteomes (UniprotKB, release 2012_01) containing forward and
reverse sequences, and the label-free quantitation algorithm as
described previously [36,38]. In MaxQuant, carbamidomethyla-
tion was set as fixed and methionine oxidation and N-acetylation
as variable modifications, using an initial mass tolerance of 6 ppm
for the precursor ion and 0.5 Da for the fragment ions. For SILAC
samples, multiplicity was set to 2 and Arg10 and Lys8 were set as
heavy label parameters. Search results were filtered with a false
discovery rate (FDR) of 0.01 for peptide and protein identifica-
tions. Protein tables were filtered to eliminate the identifications
from the reverse database and common contaminants.
In analyzing mass spectrometry data from RNA affinity
purifications, only proteins identified on the basis of at least two
peptides and a minimum of three quantitation events in at least
one experimental group were considered. Label-free quantitation
(LFQ) protein intensity values were log-transformed and missing
values filled by imputation with random numbers drawn from a
normal distribution, whose mean and standard deviation were
chosen to best simulate low abundance values. Significant
interactors of RNAs with different 59 end structures were
determined by multiple equal variance t-tests with permutation-
based false discovery rate statistics [39]. We performed 250
permutations and the FDR threshold was set between 0.02 and
0.1. The parameter S0 was empirically set between 0.2 and 1, to
separate background from specifically enriched interactors.
For data analysis from pulsed SILAC experiments, we used
log-transformed heavy to light protein ratios. Only proteins with
valid values were considered for analysis, and normalized by
dividing by the row median. Profile plots were generated using
LFQ intensities of log-transformed heavy-labelled protein
intensities. We excluded proteins containing less than 10 valid
values in all 12 measurements, and missing values were filled by
imputation. LFQ intensities were then normalized by dividing
by the row median.
Results were plotted using R (www.R-project.org) and Graph-
Pad Prism version 5.02. Multiple sequence alignments were
generated with ClustalW (http://www.ebi.ac.uk/Tools/msa/
clustalw2/).
Structural modelling
A homology model of human IFIT1 was obtained with
MODELLER [40] using the X-ray structure of human IFIT5
(4HOQ) as a structural template [20]. A pairwise sequence
alignment was generated with ClustalW (http://www.ebi.ac.uk/
Tools/msa/clustalw2/) and further refined with MODELLERs
align2d. Human IFIT1 and IFIT5 share approximately 75.6%
sequence similarity, with 57.2% of all residues being identical.
Cavity volumes in both structures were calculated in a two-step
process with the rolling probe method using 3V [41]. First, a
solvent-excluded volume was calculated for each structure using a
probe radius of 1.5 A˚ (corresponding to water). A larger probe size
of 5 A˚ was used to calculate so-called ‘‘shell volumes’’. The
solvent-accessible cavity volumes were obtained by subtraction of
each solvent-excluded volume from the corresponding shell
volume.
Supporting Information
Figure S1 Generation of 59end modified in-vitro tran-
scribed RNA. (a) Schematic overview of synthesis of the
biotinylated RNA used in this study. 59 triphosphorylated (PPP-)
7SK-antisense RNA obtained by in vitro transcription with SP6
polymerase was modified enzymatically at the 59 end by
incubating with alkaline phosphatase (AP) to remove 59 phos-
phates (OH-RNA), with recombinant Vaccinia virus capping
enzyme (VCE) to produce unmethylated capped RNA (CAP-
RNA), with VCE in the presence of S-adenosyl methionine (SAM)
to generate N7-methylated capped RNA (CAP0-RNA), or with
VCE and recombinant Vaccinia virus 29O methyltransferase
(VP39) in the presence of SAM to generate N7-methylated capped
RNA methylated at the 29O position of the first ribose (CAP1-
RNA) [43],[44]. (b) Agarose gel image showing 200 ng of in vitro
transcribed, biotinylated RNA following the enzymatic treatments
depicted in (a). (c) Evaluation of the N7- and 29O-methylation
efficiency of recombinant Vaccinia virus enzymes. Capped RNAs
produced as in (a) were incubated either with VCE or VP39 in the
presence of 3H-labeled SAM, and the incorporation efficiency was
measured by scintillation counting. 3H-labeled methyl groups were
transferred from SAM only if the RNA had not previously been
methylated (N7-methylation of CAP-RNA, and 29O methylation
of CAP0-RNA), showing that methylation of RNA by both VCE
and VP39 was maximally efficient.
(TIF)
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Figure S2 RNA affinity purifications from HeLa cell
lysates. (a) Heatmap of all proteins identified in RNA affinity
purifications from HeLa cell lysates. Hierarchical clustering of
proteins was performed on logarithmic LFQ protein intensities
using Euclidean distances. The colour code represents LFQ
intensities in rainbow colours (see colour scale). (b) Heatmap
showing hierarchical clustering (Euclidean distances) of interactors
that were significantly enriched (see Materials and Methods) in
fractions bound by at least one RNA with a modified 59 end
structure (compared to OH-RNA). The plot shows means of Z-
score transformed logarithmic LFQ intensities. Blue colours
indicate Z-score ,0, red colours indicate Z-score .0, white
indicates Z-score = 0. The saturation threshold is set at -2.25 and
+2.25. Asterisks indicate the IFIT complex. (c) Volcano plots
showing enrichment (ratio of LFQ protein intensities; x-axis) and
p-values (t-test; y-axis) of CAP1-RNA to CAP-RNA. Data are
from three independent affinity purifications. Significantly en-
riched interactors (see Materials and Methods) are separated from
background proteins (blue dots) by a hyperbolic curve (dotted line).
Among the significant interactors, IFIT proteins and FTSJD2 (red)
are highlighted.
(TIF)
Figure S3 RNA affinity purifications from lysates of
mouse embryo fibroblasts. (a–b) As in Fig. S2, but showing
proteins identified in RNA affinity purifications from mouse
embryo fibroblasts. In (b) the saturation threshold is set at 21. 5
and +1. 5. The asterisk indicates the Ifit complex.
(TIF)
Figure S4 Characterisation of the murine IFIT complex.
(a) Expression of Ifit genes in wild-type (Ifit1+/+) and Ifit1-deficient
(Ifit12/2) mouse embryonic fibroblasts (MEFs). MEFs were left
untreated, treated with 1000 U/ml IFN-a, or infected with Rift
Valley fever virus Clone13 or a mutant version of vesicular
stomatitis virus (VSV-M2) at a multiplicity of infection of 1 or
0.01, respectively. Sixteen hours later RNA was analysed by
quantitative RT-PCR for mIfit1, mIfit1c, mIfit2 and mIfit3. In
each case, one representative experiment of three is shown, with
means 6SD after normalization to the TATA-binding protein
(TBP) mRNA. (b) Heatmap of selected proteins identified in RNA
affinity purifications from cell lysates of Ifit1+/+ and Ifit12/2
MEFs. The plot shows the means of log-transformed label-free
quantitation protein intensities in rainbow colours (see colour
scale). (c) Alignment of murine and human IFIT proteins using
ClustalW. (d) Matrix showing amino acid similarity (based on
ClustalW alignment) of all murine and human IFIT proteins.
Percent similarity is indicated as color coded from white to red,
and the exact similarity is shown within each element of the
matrix.
(TIF)
Figure S5 Comparison of the RNA binding cavities of
IFIT5 and IFIT1. Sections of surface representations of the
solvent-accessible surfaces of IFIT5 (top) and IFIT1 (bottom)
are shown, with PPP-RNA bound as in IFIT5 (stick
representation, superimposed on IFIT1), and the correspond-
ing cavity volumes V calculated as described in Materials and
Methods. In our calcuations, the main RNA-binding cavity in
IFIT5 has volume of 11881 A˚3. The calculated volume of the
corresponding cavity of the modelled IFIT1, at 12627 A˚3, is
about 700 A˚3 larger.
(TIF)
Figure S6 Induction of interferon-b in wild-type and
Ifit1-deficient mouse cells. Interferon-stimulated bone mar-
row-derived macrophages (MWs) from C57/BL6 (Ifit1+/+) or Ifit1-
deficient (Ifit12/2) mice were left untreated, or infected with wild-
type MHV (WT), 29O-methyltransferase-deficient MHV (DA), or
Sendai virus (SeV). Twelve hours later total RNA was harvested
and analysed by quantitative RT-PCR for interferon b (IFN-b)
mRNA. Data from three independent experiments showing fold
change relative to untreated cells (mean 6SD) after normalization
to the TATA-binding protein (TBP) mRNA.
(TIF)
Figure S7 Translation profiles of individual proteins in
MHV-infected macrophages. Translation profiles based on
pulsed SILAC of macrophages from C75/BL6 (Ifit1+/+) and Ifit1-
deficient (Ifit12/2) mice infected with wild-type MHV (WT) or
29O methyltransferase-deficient MHV (DA) as shown in Fig. 5.
The profile plot shows normalized LFQ intensities of heavy
proteins, representing a total number of 451 proteins labelled
during the 2 h pulse period. Data show average LFQ intensities
from three independent replicates. Selected profiles are coloured
and represent MHV proteins and cellular proteins involved in
immune responses.
(TIF)
Table S1 Quantitative MS data from RNA affinity
purifications with HeLa cell lysates. Proteins identified by
LC-MS/MS from lysates of HeLa cells upon affinity purification
with different RNA baits. Table contains log-transformed and
imputed label-free quantification (LFQ) intensities of all identified
proteins. Significantly enriched proteins, p values and mean
differences from t-test based analyses are indicated.
(XLSX)
Table S2 Quantitative MS data from RNA affinity
purifications with MEF lysates. Proteins identified by LC-
MS/MS from lysates of mouse embryo fibroblasts (MEF) upon
affinity purification with different RNA baits. Table contains log-
transformed and imputed label-free quantification (LFQ) intensi-
ties of all identified proteins. Significantly enriched proteins, p
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